Payment overview · 2025
General Payments
$1,785.35
103 reported records · 33 companies
Healthcare provider profile · identity verified
Harold W Cox, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, AL · NPI 1114991072
Verified facts
What the public records show
CMS Open Payments records show Harold W Cox, MD received $1,785.35 in general payments during 2025 across 103 reported records.
ABBVIE INC. accounted for 9.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Nexletol, Ozempic, Paxlovid, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 457 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.43 | 9.3% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.66 | 8.4% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $137.78 | 7.7% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.18 | 6.3% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $106.06 | 5.9% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $95.29 | 5.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.98 | 4.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.78 | 4.8% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $78.11 | 4.4% | 5 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $77.29 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.22 | 4.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.64 | 4.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.16 | 3.6% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $56.93 | 3.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.11 | 2.8% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $37.41 | 2.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.03 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.03 | 1.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.41 | 1.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $25.13 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.93 | 1.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.41 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.58 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.02 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.53 | 1.0% | 1 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.64 | 0.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.44 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.56 | 0.8% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.67 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,785.35 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $217.37 | 12 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $137.78 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.42 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.78 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $78.11 | 5 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $77.29 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $75.59 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $75.59 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $75.59 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.22 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.22 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.64 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.16 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.01 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $56.93 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.11 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.63 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.41 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 40 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 457 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 150 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 327 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 243 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 60 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
109 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
243 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
109 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
457 | 79 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 828 | 185 |
| Pantoprazole Sodium | Pantoprazole Sodium | 679 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 650 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 522 | 144 |
| Eliquis | Apixaban | 457 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 425 | 136 |
| Trazodone Hcl | Trazodone Hcl | 406 | 118 |
| Furosemide | Furosemide | 403 | 112 |
| Pravastatin Sodium | Pravastatin Sodium | 387 | 105 |
| Alprazolam | Alprazolam | 386 | 51 |
| Tramadol Hcl | Tramadol Hcl | 381 | 74 |
| Omeprazole | Omeprazole | 380 | 98 |
| Carvedilol | Carvedilol | 379 | 96 |
| Losartan Potassium | Losartan Potassium | 345 | 95 |
| Jardiance | Empagliflozin | 327 | 60 |
| Potassium Chloride | Potassium Chloride | 318 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 83 |
| Memantine Hcl | Memantine Hcl | 305 | 69 |
| Montelukast Sodium | Montelukast Sodium | 295 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 76 |
| Famotidine | Famotidine | 278 | 79 |
| Lisinopril | Lisinopril | 276 | 69 |
| Labetalol Hcl | Labetalol Hcl | 274 | 73 |
| Metformin Hcl | Metformin Hcl | 254 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 246 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 245 | 62 |
| Ozempic | Semaglutide | 243 | 50 |
| Fluconazole | Fluconazole | 223 | 73 |
| Donepezil Hcl | Donepezil Hcl | 196 | 42 |
| Glipizide | Glipizide | 196 | 54 |
| Clonazepam | Clonazepam | 193 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 166 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 166 | 34 |
| Meloxicam | Meloxicam | 161 | 44 |
| Raloxifene Hcl | Raloxifene Hcl | 161 | 47 |
| Sertraline Hcl | Sertraline Hcl | 158 | 46 |
| Xarelto | Rivaroxaban | 156 | 21 |
| Alendronate Sodium | Alendronate Sodium | 153 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 60 |
| Ezetimibe | Ezetimibe | 152 | 46 |
| Farxiga | Dapagliflozin Propanediol | 150 | 35 |
| Pregabalin | Pregabalin | 146 | 31 |
| Allopurinol | Allopurinol | 142 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 42 |
| Spironolactone | Spironolactone | 141 | 37 |
| Mirtazapine | Mirtazapine | 140 | 35 |
| Solifenacin Succinate | Solifenacin Succinate | 139 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 31 |
| Januvia | Sitagliptin Phosphate | 137 | 18 |
| Clonidine Hcl | Clonidine Hcl | 134 | 43 |
| Myrbetriq | Mirabegron | 134 | 21 |
| Buspirone Hcl | Buspirone Hcl | 132 | 31 |
| Baclofen | Baclofen | 129 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 26 |
| Ramipril | Ramipril | 120 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 111 | 26 |
| Rexulti | Brexpiprazole | 109 | 13 |
| Divalproex Sodium | Divalproex Sodium | 103 | 31 |
| Methocarbamol | Methocarbamol | 97 | 41 |
| Primidone | Primidone | 97 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 97 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 25 |
| Valsartan | Valsartan | 88 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 34 |
| Topiramate | Topiramate | 85 | 20 |
| Estradiol | Estradiol | 84 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 27 |
| Mounjaro | Tirzepatide | 84 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 25 |
| Prednisone | Prednisone | 81 | 55 |
| Entresto | Sacubitril/Valsartan | 79 | suppressed |
| Rybelsus | Semaglutide | 78 | 13 |
| Simvastatin | Simvastatin | 78 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 23 |
| Nifedipine Er | Nifedipine | 76 | 20 |
| Vilazodone Hcl | Vilazodone Hcl | 75 | 18 |
| Vascepa | Icosapent Ethyl | 74 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 33 |
| Azithromycin | Azithromycin | 71 | 62 |
| Nortriptyline Hcl | Nortriptyline Hcl | 71 | 20 |
| Glimepiride | Glimepiride | 68 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 18 |
| Ondansetron Odt | Ondansetron | 66 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 64 | suppressed |
| Celecoxib | Celecoxib | 63 | 19 |
| Colestipol Hcl | Colestipol Hcl | 62 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 16 |
| Temazepam | Temazepam | 62 | suppressed |
| Levetiracetam | Levetiracetam | 61 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 61 | 30 |
| Olanzapine | Olanzapine | 61 | 12 |
| Telmisartan | Telmisartan | 61 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 59 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 58 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 48 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 54 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 14 |
| Propranolol Hcl | Propranolol Hcl | 54 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 27 |
| Trulicity | Dulaglutide | 53 | 16 |
| Linzess | Linaclotide | 52 | 17 |
| Digoxin | Digoxin | 51 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 50 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Mometasone Furoate | Mometasone Furoate | 49 | 12 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Gemtesa | Vibegron | 47 | suppressed |
| Dutasteride | Dutasteride | 46 | 17 |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 14 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Azelastine Hcl | Azelastine Hcl | 45 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 11 |
| Midodrine Hcl | Midodrine Hcl | 45 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Sucralfate | Sucralfate | 44 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 12 |
| Cephalexin | Cephalexin | 43 | 31 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | 11 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 42 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 41 | 23 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 40 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | 12 |
| Aripiprazole | Aripiprazole | 37 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Dexamethasone | Dexamethasone | 37 | 23 |
| Pilocarpine Hcl | Pilocarpine Hcl | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Finasteride | Finasteride | 36 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 11 |
| Kerendia | Finerenone | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Modafinil | Modafinil | 33 | suppressed |
| Naproxen | Naproxen | 33 | 12 |
| Nystatin | Nystatin | 33 | 15 |
| Fluocinonide | Fluocinonide | 32 | 18 |
| Ketoconazole | Ketoconazole | 32 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Atenolol | Atenolol | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 28 |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 20 |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Indapamide | Indapamide | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Testosterone | Testosterone | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Felodipine Er | Felodipine | 24 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Sulindac | Sulindac | 23 | suppressed |
| Cimetidine | Cimetidine | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Galantamine Er | Galantamine Hbr | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Penicillin V Potassium | Penicillin V Potassium | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 15 |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,785.35 · 103 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Da Vinci Surgical System, ELIQUIS, FARXIGA, Flucelvax, GEMTESA, IBSRELA, INGREZZA, INSPIRE, JARDIANCE, JATENZO, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Sunosi, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, YUPELRI, ZEPBOUND, Zypitamag | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error